Skip to main content
. 2011 Jan 13;18(5):488–495. doi: 10.1038/gt.2010.170

Figure 5.

Figure 5

Antitumor activity of mesenchymal stem cells (MSCs) expressing modified interleukin-12 embedded in Matrigel (MSCs/IL-12M/Matrigel) in various immune cell-deficient mice. C57BL/6, Beige, CD8+ T-cell-depleted, BNX, SCID and interferon (IFN)-γ knockout mice were injected with B16F10 tumor cells as described in Figure 1 legend. One day after i.v. B16F10 injection, mice were treated with MSCs/IL-12M/Matrigel twice as indicated by arrows. Depletion of CD8+ T cells was performed as described in materials and methods. The treated mice were assessed for tumor growth (a), number of lung metastases (b) and survival rates (c). Similar results were obtained in another independent experiment. *P<0.05 and **P<0.01.